Drug treatment with Cymbalta
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Depression
Conditions
Depression, Bereavement
Trial Timeline
Apr 1, 2008 → Apr 1, 2010
NCT ID
NCT00658931About Drug treatment with Cymbalta
Drug treatment with Cymbalta is a approved stage product being developed by Eli Lilly for Depression. The current trial status is unknown. This product is registered under clinical trial identifier NCT00658931. Target conditions include Depression, Bereavement.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00658931 | Approved | UNKNOWN |
Competing Products
20 competing products in Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine and Fluoxetine combination (OFC) + Fluoxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Approved | 85 |
| FK949E | Astellas Pharma | Phase 3 | 77 |
| Quetiapine | Astellas Pharma | Pre-clinical | 23 |
| duloxetine + escitalopram + placebo | Eli Lilly | Phase 3 | 77 |
| duloxetine | Eli Lilly | Approved | 85 |
| Duloxetine Hydrochloride | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Approved | 85 |
| Duloxetine | Eli Lilly | Approved | 85 |
| Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro) | Eli Lilly | Approved | 85 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Approved | 85 |
| duloxetine + fluoxetine + citalopram + paroxetine + sertraline | Eli Lilly | Approved | 85 |
| Olanzapine + Placebo | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Fluoxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| duloxetine + duloxetine | Eli Lilly | Pre-clinical | 23 |
| olanzapine + ziprasidone | Eli Lilly | Approved | 85 |
| Olanzapine Fluoxetine Combination (OFC) + Placebo | Eli Lilly | Approved | 85 |
| Duloxetine | Eli Lilly | Approved | 85 |
| Duloxetine | Eli Lilly | Approved | 85 |